Abstract
Background Chronic inflammatory disorders after ileal pouch-anal anastomosis (IPAA) surgery are common. These include chronic pouchitis, Crohn’s disease of the pouch, prepouch ileitis, and rectal cuff inflammation. The aim of this study was to evaluate the efficacy of biologic therapies in treating these disorders.
Method Systematic review of all published studies from inception to April 1st, 2021 was performed to investigate the efficacy of biologic therapies for post IPAA chronic inflammatory disorders. The primary outcome was the efficacy of biologic therapies in achieving complete response or remission. A subgroup analysis was performed for each disorder separately.
Results A total of 24 studies were identified including 682 patients. Using a random effect model, the overall pooled efficacy of biologic therapies in achieving complete response or remission in patients with post IPAA surgery chronic inflammatory disorders was 60% (95% Confidence Interval (CI), 56 - 64). Specifically, the pooled efficacy of ustekinumab was 75% (95% CI, 64 - 85, p = 0.007), whereas the efficacy of vedolizumab was 60% (95% CI, 52 - 68, p = 0.172). In addition, the efficacy infliximab and adalimumab were 59% (95% CI, 53 - 64, p <0.01) and 51% (95% CI, 42 - 60, p = 0.452) respectively.
Conclusion Ustekinumab, infliximab, vedolizumab and adalimumab are effective in achieving complete response or remission in post IPAA surgery chronic inflammatory disorders. There is also a clear trend toward higher efficacy in patients with Crohn’s disease of the pouch compared to chronic pouchitis. More studies are needed to determine the efficacy of biologics in cuffitis.
Summary Chronic inflammatory disorders after ileal pouch-anal anastomosis surgery are common. These include chronic pouchitis, Crohn’s disease of the pouch, prepouch ileitis, and rectal cuff inflammation. This study aimed to evaluate the efficacy of biologic therapies in achieving complete response or remission in these disorders.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
not a clinical trial
Funding Statement
No external funding received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declaration: All authors declare no conflict of interest or financial support.
Data Availability
All research data available with the submitted documents.
